Time-resolved FRET between GPCR ligands reveals oligomers in native tissues

Nature Chemical Biology

Volumn 6, Issue 8, 2010, Pages 587-594

  Albizu, Laura ^a,b,c,j   Cottet, Martin ^a,b,c   Kralikova, Michaela ^d,e,k   Stoev, Stoytcho ^f   Seyer, René ^a,b,c   Brabet, Isabelle ^a,b,c   Roux, Thomas ^g   Bazin, Hervé ^g   Bourrier, Emmanuel ^g   Lamarque, Laurent ^g   Breton, Christophe ^h   Rives, Marie Laure ^d,e   Newman, Amy ⁱ   Javitch, Jonathan ^d,e   Trinquet, Eric ^g   Manning, Maurice ^f   Pin, Jean Philippe ^a,b,c   Mouillac, Bernard ^a,b,c   Durroux, Thierry ^a,b,c  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b Institute National de la Santé et de la Recherche Medicinale   (France)

^c UNIV MONTPELLIER   (France)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f Emergency Medicine   (United States)

^g Cisbio Bioassays   (France)

^h UNIV LILLE   (France)

ⁱ NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k Mount Sinai School of Medicine ^*  (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; OLIGOMER; OXYTOCIN RECEPTOR; DOPAMINE 2 RECEPTOR; FLUORESCENT DYE; OLIGOPEPTIDE; VASOPRESSIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE RESONANCE ENERGY TRANSFER; LIGAND BINDING; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ALGORITHM; ANIMAL; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; METABOLISM; METHODOLOGY; RADIOASSAY; UDDER;

ALGORITHMS; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; LIGANDS; MAMMARY GLANDS, ANIMAL; MODELS, MOLECULAR; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN;

EID: 77955874300     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.396     Document Type: Article

References (50)

1. Terrillon, S. & Bouvier, M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5, 30-34 (2004).
2. Ferré, S. et al. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134 (2009).
3. Fotiadis, D. et al. Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. Curr. Opin. Struct. Biol. 16, 252-259 (2006).
4. Gomes, I. et al. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. USA 101, 5135-5139 (2004).
5. Wreggett, K.A. & Wells, J.W. Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J. Biol. Chem. 270, 22488-22499 (1995).
6. Chidiac, P., Green, M.A., Pawagi, A.B. & Wells, J.W. Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. Biochemistry 36, 7361-7379 (1997). (Pubitemid 27262359)
7. Urizar, E. et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. 24, 1954-1964 (2005).
8. Waldhoer, M. et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. USA 102, 9050-9055 (2005).
9. Roess, D.A., Horvat, R.D., Munnelly, H. & Barisas, B.G. Luteinizing hormone receptors are self-associated in the plasma membrane. Endocrinology 141, 4518-4523 (2000).
10. Patel, R.C. et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. USA 99, 3294-3299 (2002).
11. Bazin, H., Trinquet, E. & Mathis, G. Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions. J. Biotechnol. 82, 233-250 (2002).
12. Terrillon, S. et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol. 17, 677-691 (2003).
13. Devost, D. & Zingg, H.H. Identification of dimeric and oligomeric complexes of the human oxytocin receptor by co-immunoprecipitation and bioluminescence resonance energy transfer. J. Mol. Endocrinol. 31, 461-471 (2003).
14. Cottet, M. et al. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes. Curr. Opin. Pharmacol. 1, 59-66 (2009).
15. Armstrong, D. & Strange, P.G. Dopamine D2 receptor dimer formation: evidence from ligand binding. J. Biol. Chem. 276, 22621-22629 (2001).
16. Guo, W. et al. Dopamine D2 receptors form higher-order oligomers at physiological expression levels. EMBO J. 27, 2293-2304 (2008).
17. Javitch, J.A. The ants go marching two by two: oligomeric structure of G-protein-coupled receptors. Mol. Pharmacol. 66, 1077-1082 (2004).
18. Vivo, M., Lin, H. & Strange, P.G. Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Mol. Pharmacol. 69, 226-235 (2006).
19. Albizu, L. et al. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol. Pharmacol. 70, 1783-1791 (2006).
20. Albizu, L. et al. Towards efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J. Med. Chem. 50, 4976-4985 (2007).
21. Durroux, T. et al. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications. J. Med. Chem. 42, 1312-1319 (1999).
22. Mathis, G. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41, 1391-1397 (1995).
23. Selvin, P.R. & Hearst, J.E. Luminescence energy transfer using a terbium chelate: improvements on fluorescence energy transfer. Proc. Natl. Acad. Sci. USA 91, 10024-10028 (1994).
24. Mouillac, B., Manning, M. & Durroux, T. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Rev. Med. Chem. 8, 996-1005 (2008).
25. Chini, B. et al. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 397, 201-206 (1996).
26. Serradeil-Le Gal, C. et al. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 58, 1613-1622 (2000).
27. Maurel, D. et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat. Methods 5, 561-567 (2008).
28. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002).
29. Durroux, T. Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol. Sci. 26, 376-384 (2005).
30. Christopoulos, A., Lanzafame, A., Ziegler, A. & Mitchelson, F. Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an "infinite dilution" procedure. Biochem. Pharmacol. 53, 795-800 (1997).
31. Breton, C. et al. Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. J. Biol. Chem. 276, 26931-26941 (2001).
32. Cotte, N. et al. Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J. Biol. Chem. 273, 29462-29468 (1998).
33. Mouillac, B. et al. Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors. Adv. Exp. Med. Biol. 449, 359-361 (1998).
34. Phalipou, S. et al. Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J. Biol. Chem. 272, 26536-26544 (1997).
35. Terrillon, S. et al. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J. Med. Chem. 45, 2579-2588 (2002).
36. Han, Y., Moreira, I.S., Urizar, E., Weinstein, H. & Javitch, J.A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688-695 (2009).
37. Barki-Harrington, L., Luttrell, L.M. & Rockman, H.A. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108, 1611-1618 (2003).
38. Damian, M., Martin, A., Mesnier, D., Pin, J.P. & Baneres, J.L. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 25, 5693-5702 (2006).
39. Guo, W., Shi, L. & Javitch, J.A. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J. Biol. Chem. 278, 4385-4388 (2003).
40. Vilardaga, J.P. et al. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol. 4, 126-131 (2008).
41. Springael, J.Y. et al. Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol. Pharmacol. 69, 1652-1661 (2006).
42. Goudet, C. et al. Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J. Biol. Chem. 280, 24380-24385 (2005).
43. Hlavackova, V. et al. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 24, 499-509 (2005).
44. Springael, J.Y., Urizar, E. & Parmentier, M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev. 16, 611-623 (2005).
45. Ciruela, F. et al. Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J. Biol. Chem. 276, 18345-18351 (2001).
46. Sohy, D. et al. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J. Biol. Chem. 284, 31270-31279 (2009).
47. Daniels, D.J. et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. USA 102, 19208-19213 (2005).
48. Hague, C., Uberti, M.A., Chen, Z., Hall, R.A. & Minneman, K.P. Cell surface expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors. J. Biol. Chem. 279, 15541-15549 (2004).
49. Chabre, M., Deterre, P. & Antonny, B. The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol. Sci. 30, 182-187 (2009).
50. Rives, M.L. et al. Crosstalk between GABA(B) and mGlu1a receptors reveals new insight into GPCR signal integration. EMBO J. 28, 2195-2208 (2009).